Petrelintide

Zealand Pharma

Petrelintide is an experimental amylin receptor agonist engineered for once-weekly subcutaneous dosing. Amylin is a hormone co-released with insulin that promotes satiety, slows gastric emptying, and helps regulate post-meal glucose. Drugs that mimic amylin are attractive in obesity because they suppress appetite through a mechanism that is complementary to GLP-1 and may come with a gentler gastrointestinal profile, and because amylin biology is thought to support a favorable composition of weight loss. Zealand Pharma is developing petrelintide as a stand-alone amylin analog and as a candidate backbone for combinations with incretin drugs, and the program has attracted major partnership interest. Early-phase clinical results reported single-digit to near-double-digit percentage weight loss over a few months of dosing, with tolerability that its developers highlight as a differentiator versus GLP-1-heavy regimens. As with all agents on this page, petrelintide is investigational, not approved anywhere, and not legally available for purchase; the numbers so far come from early trials and require confirmation in larger Phase 2 and Phase 3 studies. It is included as an educational reference on the emerging class of amylin-based obesity drugs.